These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 8292298

  • 1. Activation of dermal connective tissue in scleroderma.
    Kähäri VM.
    Ann Med; 1993 Dec; 25(6):511-8. PubMed ID: 8292298
    [Abstract] [Full Text] [Related]

  • 2. Connective tissue metabolism including cytokines in scleroderma.
    Smith EA.
    Curr Opin Rheumatol; 1992 Dec; 4(6):869-77. PubMed ID: 1457283
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of skin fibrosis in systemic sclerosis.
    Jinnin M.
    J Dermatol; 2010 Jan; 37(1):11-25. PubMed ID: 20175837
    [Abstract] [Full Text] [Related]

  • 4. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
    Chujo S, Shirasaki F, Kawara S, Inagaki Y, Kinbara T, Inaoki M, Takigawa M, Takehara K.
    J Cell Physiol; 2005 May; 203(2):447-56. PubMed ID: 15605379
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.
    Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J.
    Arthritis Rheum; 2004 Apr; 50(4):1305-18. PubMed ID: 15077315
    [Abstract] [Full Text] [Related]

  • 7. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha.
    Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, Dayer JM.
    Arthritis Rheum; 2003 Sep; 48(9):2593-604. PubMed ID: 13130479
    [Abstract] [Full Text] [Related]

  • 8. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta.
    Bhattacharyya S, Ghosh AK, Pannu J, Mori Y, Takagawa S, Chen G, Trojanowska M, Gilliam AC, Varga J.
    Arthritis Rheum; 2005 Apr; 52(4):1248-58. PubMed ID: 15818659
    [Abstract] [Full Text] [Related]

  • 9. [Pathophysiology of fibroses. Progressive systemic scleroderma as a model disease].
    Hein R, Mauch C, Braun-Falco O, Krieg T.
    Hautarzt; 1988 Feb; 39(2):65-71. PubMed ID: 3283077
    [Abstract] [Full Text] [Related]

  • 10. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts.
    Mori Y, Chen SJ, Varga J.
    Arthritis Rheum; 2003 Jul; 48(7):1964-78. PubMed ID: 12847691
    [Abstract] [Full Text] [Related]

  • 11. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet.
    Lakos G, Melichian D, Wu M, Varga J.
    Pathobiology; 2006 Jul; 73(5):224-37. PubMed ID: 17314493
    [Abstract] [Full Text] [Related]

  • 12. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N, Brinckmann J.
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [Abstract] [Full Text] [Related]

  • 13. Immunological modulation of dermal fibroblasts in scleroderma.
    Perlish JS, Fleischmajer R.
    Immunol Ser; 1989 Jan; 46():605-24. PubMed ID: 2488871
    [Abstract] [Full Text] [Related]

  • 14. The roles of transforming growth factor type beta3 (TGF-beta3) and mast cells in the pathogenesis of scleroderma.
    Ozbilgin MK, Inan S.
    Clin Rheumatol; 2003 Sep; 22(3):189-95. PubMed ID: 14505209
    [Abstract] [Full Text] [Related]

  • 15. Animal models of scleroderma: lessons from transgenic and knockout mice.
    Derrett-Smith EC, Denton CP, Sonnylal S.
    Curr Opin Rheumatol; 2009 Nov; 21(6):630-5. PubMed ID: 19730378
    [Abstract] [Full Text] [Related]

  • 16. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.
    Pannu J, Gore-Hyer E, Yamanaka M, Smith EA, Rubinchik S, Dong JY, Jablonska S, Blaszczyk M, Trojanowska M.
    Arthritis Rheum; 2004 May; 50(5):1566-77. PubMed ID: 15146427
    [Abstract] [Full Text] [Related]

  • 17. Cytokine regulation of prolyl 4-hydroxylase production in skin fibroblast cultures from patients with systemic sclerosis: contribution to collagen synthesis and fibrosis.
    Kawaguchi Y, Kitani A, Hara M, Harigai M, Hirose T, Suzuki K, Kawakami M, Hidaka T, Ishizuka T, Kawagoe M.
    J Rheumatol; 1992 Aug; 19(8):1195-201. PubMed ID: 1328634
    [Abstract] [Full Text] [Related]

  • 18. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors.
    Ihn H, Yamane K, Kubo M, Tamaki K.
    Arthritis Rheum; 2001 Feb; 44(2):474-80. PubMed ID: 11229480
    [Abstract] [Full Text] [Related]

  • 19. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.
    Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, Jablonska S, Blaszczyk M, Watson DK, Trojanowska M.
    Am J Pathol; 2003 Aug; 163(2):571-81. PubMed ID: 12875977
    [Abstract] [Full Text] [Related]

  • 20. TGF beta--a role in systemic sclerosis?
    Cotton SA, Herrick AL, Jayson MI, Freemont AJ.
    J Pathol; 1998 Jan; 184(1):4-6. PubMed ID: 9582519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.